GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

The issuer is solely responsible for the content of this announcement.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.